These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 31004045)

  • 41. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.
    Gianni L; Eiermann W; Semiglazov V; Lluch A; Tjulandin S; Zambetti M; Moliterni A; Vazquez F; Byakhov MJ; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Magazzù D; Heinzmann D; Steinseifer J; Valagussa P; Baselga J
    Lancet Oncol; 2014 May; 15(6):640-7. PubMed ID: 24657003
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.
    Majewski IJ; Nuciforo P; Mittempergher L; Bosma AJ; Eidtmann H; Holmes E; Sotiriou C; Fumagalli D; Jimenez J; Aura C; Prudkin L; Díaz-Delgado MC; de la Peña L; Loi S; Ellis C; Schultz N; de Azambuja E; Harbeck N; Piccart-Gebhart M; Bernards R; Baselga J
    J Clin Oncol; 2015 Apr; 33(12):1334-9. PubMed ID: 25559818
    [TBL] [Abstract][Full Text] [Related]  

  • 43. MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy.
    van Ramshorst MS; Loo CE; Groen EJ; Winter-Warnars GH; Wesseling J; van Duijnhoven F; Peeters MTV; Sonke GS
    Breast Cancer Res Treat; 2017 Jul; 164(1):99-106. PubMed ID: 28432515
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
    Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
    Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dual Block with Lapatinib and Trastuzumab Versus Single-Agent Trastuzumab Combined with Chemotherapy as Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Meta-analysis of Randomized Trials.
    Clavarezza M; Puntoni M; Gennari A; Paleari L; Provinciali N; D'Amico M; DeCensi A
    Clin Cancer Res; 2016 Sep; 22(18):4594-603. PubMed ID: 27140927
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy.
    Pascual T; Fernandez-Martinez A; Tanioka M; Dieci MV; Pernas S; Gavila J; Guarneri V; Cortes J; Villagrasa P; Chic N; Vidal M; Adamo B; Muñoz M; Griguolo G; Llombart A; Conte P; Oliveira M; Conte B; Paré L; Galvan P; Carey LA; Perou CM; Prat A
    Clin Cancer Res; 2021 Jun; 27(11):3116-3125. PubMed ID: 33632929
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.
    Bianchini G; Kiermaier A; Bianchi GV; Im YH; Pienkowski T; Liu MC; Tseng LM; Dowsett M; Zabaglo L; Kirk S; Szado T; Eng-Wong J; Amler LC; Valagussa P; Gianni L
    Breast Cancer Res; 2017 Feb; 19(1):16. PubMed ID: 28183321
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neoadjuvant Therapy for HER2-positive Breast Cancer.
    Wuerstlein R; Harbeck N
    Rev Recent Clin Trials; 2017; 12(2):81-92. PubMed ID: 28164759
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
    Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
    Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer: loss of HER2 amplification and its impact on response and prognosis.
    Wang RX; Chen S; Jin X; Chen CM; Shao ZM
    Breast Cancer Res Treat; 2017 Jan; 161(2):259-267. PubMed ID: 27885439
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials.
    Fernandez-Martinez A; Rediti M; Tang G; Pascual T; Hoadley KA; Venet D; Rashid NU; Spears PA; Islam MN; El-Abed S; Bliss J; Lambertini M; Di Cosimo S; Huobe J; Goerlitz D; Hu R; Lucas PC; Swain SM; Sotiriou C; Perou CM; Carey LA
    JAMA Oncol; 2024 May; 10(5):603-611. PubMed ID: 38546612
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Human epidermal growth factor receptor 2-positive breast cancer: heat shock protein 90 overexpression, Ki67 proliferative index, and topoisomerase II-α co-amplification as predictors of pathologic complete response to neoadjuvant chemotherapy with trastuzumab and docetaxel.
    Bria E; Furlanetto J; Carbognin L; Brunelli M; Caliolo C; Nortilli R; Massari F; Pedron S; Manfrin E; Pellini F; Bonetti F; Sperduti I; Pollini GP; Scarpa A; Tortora G
    Clin Breast Cancer; 2015 Feb; 15(1):16-23. PubMed ID: 25034441
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Proliferation Determined by Ki-67 Defines Different Pathologic Response to Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer.
    Sánchez-Muñoz A; Navarro-Perez V; Plata-Fernández Y; Santonja A; Moreno I; Ribelles N; Alba E
    Clin Breast Cancer; 2015 Oct; 15(5):343-7. PubMed ID: 25752727
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Is Multifocal Regression a Risk Factor for Ipsilateral Breast Tumor Recurrence in the Modern Era After Neoadjuvant Chemotherapy and Breast Conservation Therapy?
    Ling DC; Sutera PA; Iarrobino NA; Diego EJ; Soran A; Johnson RR; Bhargava R; Champ CE; Beriwal S
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):869-876. PubMed ID: 30885777
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.
    Gianni L; Bisagni G; Colleoni M; Del Mastro L; Zamagni C; Mansutti M; Zambetti M; Frassoldati A; De Fato R; Valagussa P; Viale G
    Lancet Oncol; 2018 Feb; 19(2):249-256. PubMed ID: 29326029
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients.
    Guarneri V; Dieci MV; Barbieri E; Piacentini F; Omarini C; Ficarra G; Bettelli S; Conte PF
    Ann Oncol; 2013 Dec; 24(12):2990-4. PubMed ID: 24013581
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect and safety of dual anti-human epidermal growth factor receptor 2 therapy compared to monotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: a systematic review.
    Zhang X; Zhang XJ; Zhang TY; Yu FF; Wei X; Li YS; He J
    BMC Cancer; 2014 Aug; 14():625. PubMed ID: 25164542
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I; Tuxen MK; Nielsen DL
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy for human epidermal growth factor receptor 2 positive breast cancer: a real-world retrospective single-institutional study in China.
    Peng DM; Li J; Qiu JX; Zhao L
    World J Surg Oncol; 2024 Apr; 22(1):88. PubMed ID: 38582875
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy.
    Weiss A; Bashour SI; Hess K; Thompson AM; Ibrahim NK
    Breast Cancer Res; 2018 Apr; 20(1):27. PubMed ID: 29661243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.